

## Interaction Report

Report ID:

Date Produced:

15 May 2025

## Antiretroviral Treatment

## Co-medications

Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir  
alafenamide (EVG/c/FTC/TAF)

Sildenafil (Erectile Dysfunction)

This report lists the summaries of potential interactions (i.e. "red", "amber" and "yellow" classifications) for the drugs in the table above.

Interactions with a "green" or "grey" classification (i.e. no clinically significant interaction or no clear data) have been checked and are listed at the end of this report, but summaries are not shown.

For full details of all interactions, see [www.hiv-druginteractions.org](http://www.hiv-druginteractions.org).

## Description of the interactions

Potential clinically significant interaction - likely to require additional monitoring, alteration of drug dosage or timing of administration (AMBER)

Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir alafenamide (EVG/c/FTC/TAF) + Sildenafil (Erectile Dysfunction)  
Coadministration has not been studied but elvitegravir/cobicistat is expected to substantially increase sildenafil concentrations and may result in an increase in associated adverse events including hypotension, syncope, visual changes and prolonged erection. Use sildenafil with caution at a reduced dose not exceeding 25 mg in 48 h with increased monitoring for adverse events. Emtricitabine and tenofovir alafenamide do not interact with sildenafil.